SCOPE-PD: Explainable AI on Subjective and Clinical Objective Measurements of Parkinson’s Disease for Precision Decision-Making

Md Mezbahul Islam, John Michael Templeton, Masrur Sobhan, Christian Poellabauer, Ananda Mohan Mondal · 2026

Read SCOPE-PD: Explainable AI on Subjective and Clinical Objective Measurements of Parkinson’s Disease for Precision Decision-Making by Md Mezbahul Islam, John Michael Templeton, Masrur Sobhan, Christian Poellabauer, Ananda Mohan Mondal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2601-22516.txt.

Introduction

Md Mezbahul Islam and a team built SCOPE-PD, a tool to call Parkinson's disease early and say why. Parkinson's is a slow brain disease shaped by genes, health, and life habits. Their 2026 preprint notes that standard checks lean on judgment calls, which can delay a firm diagnosis.

The tool joins what patients report with hard clinical measures. It aims at precision care: the right call, for the right person, in time to help. An explainable call lets doctors check the logic, not just trust a score. The work targets a real clinic need.

Catalog record

CREATORMd Mezbahul Islam, John Michael Templeton, Masrur Sobhan, Christian Poellabauer, Ananda Mohan Mondal
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2601-22516

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

SCOPE-PD: Explainable AI on Subjective and Clinical Objective Measurements of Parkinson’s Disease for Precision Decision-Making Md Mezbahul Islam, John Michael Templeton, Masrur Sobhan, Christian Poellabauer, Ananda Mohan Mondal Abstract Parkinson’s disease (PD) is a chronic and complex neurodegenerative disorder influenced by genetic, clinical, and lifestyle factors. Predicting this disease early is challenging because it depends on traditional diagnostic methods that face issues of subjectivity, which commonly delay diagnosis. Several objective analyses are currently in practice to help overcome the challenges of subjectivity; however, a proper explanation of these analyses is still lacking. While machine learning (ML) has demonstrated potential in supporting PD diagnosis, existing approaches often rely on subjective reports only and lack interpretability for individualized risk estimation. This study proposed SCOPE-PD, an explainable AI-based prediction framework by integrating subjective and objective assessments to provide personalized health decisions. Subjective and objective clinical assessment data are collected from the Parkinson’s Progression Markers Initiative (PPMI) study to construct a multimodal prediction framework. Several ML techniques were applied to these data, and the best ML model was selected to interpret the results. Model interpretability was examined using SHAP-based analysis. The Random Forest algorithm achieved the highest accuracy of 98.66% while working with the combined features from both subjective and objective test data. Tremor, bradykinesia, and facial expression are identified as the top three contributing features from the MDS-UPDRS test in the prediction of PD. keywords Parkinson’s Disease, Machine Learning, Explainable Artificial Intelligence, Precision treatment, Clinical decision-making, Multi-modal Analysis. 1 Introduction Parkinson’s disease (PD) has emerged as one of the most pressing neurodegenerative challenges worldwide, affecting an estimated 11.8 million people as of 2021—a number projected to rise dramatically to over 25 million by 2050 as the global population ages 14 . This rise not only puts a lot of stress on people and society, but it also makes the need for a quick and accurate diagnosis even more urgent, especially since there is still no cure that can improve the course of the disease. PD usually shows up as a mix of motor and non-motor symptoms caused by neurodegenerative changes, including the death of dopaminergic neurons and the buildup of alpha-synuclein aggregates 28 . The effects of PD on people and their families go beyond the emotional, cognitive, and physical effects. Additionally, the cost involved in diagnosing, monitoring, and treating PD is also rising, and it is now thought to be over USD 50 billion a year in the United States alone 3 , which points to the need for earlier and more accurate diagnosis. Even though neurological assessment has reached an advanced level, diagnostic accuracy is still low, at 70%-80%, especially in early stages. Clinical assessments are a big part of PD care and research, as they are the basis for diagnosis and the main way to record how the disease is getting worse. Traditionally, these assessments comprise a combination of subjective tests (e.g., patient-reported outcomes, questionnaires) and objective measures (e.g., clinician-rated motor and cognitive examinations). Although subjective and objective tools work well together to help doctors make decisions, their differences lead to ongoing debates about the best way to do things 19 . Finding a balance is important for both the accuracy of research and the care of patients. Recent evidence also suggests that patient-reported outcomes can meaningfully reflect underlying biological mechanisms, as demonstrated in REDONE-PD, where dopamine-related genetic mutations showed measurable associations with neurocognitive and functional outcomes in both PD patients and healthy controls 10 . Numerous studies have leveraged ML for the early detection of PD, harnessing everything from clinical diagnosis, sensor data, and voice characteristics to sophisticated neuroimaging. Grover et al. utilized voice recordings to accurately predict Parkinson’s disease; however, medical history and cognitive data were excluded 8 . Templeton et al. found that perceived functionality by patients often differs from sensor-based metrics by applying ML while doing precise, stage-specific assessment and feature identification in PD 23 . Adebimp et al. developed an explainable ML pipeline for PD prediction using a multimodal dataset that combines demographics, medical history, lifestyle, symptoms, and standard clinical assessments (e.g., UPDRS, MoCA) with 93% prediction accuracy 5 . Pereira et al. effectively employed movement analysis, yet they did not consider lifestyle and demographic factors 16 . A central barrier to broad clinical implementation of ML models lies in their “black box” nature. Without clear, patient-specific rationales for predictions, both clinicians and patients may be reluctant to trust or act on ML-driven insights. E X plainable AI (XAI) techniques, such as SHapley Additive exPlanations (SHAP) 13 , address this issue by clarifying how predictions are made in complex health sectors (e.g., cancer 21 , depression 24 ). Adebimp et al., who applied SHAP for PD prediction, did not consider explaining from patient-reported and expert-assessed aspects. Figure 1: Overall Study Framework including Data Description, Data Preprocessing, Classification Algorithms, and Explanation Technique and Precision Clinical Decision. EPW: Epworth Sleepiness Scale; MDS-UPDRS: Movement Disorder Society Unified Parkinson’s Disease Rating Scale; REM: Rapid Eye Movement; SCOPA-AUT: Scales for Outcomes in Parkinson’s disease - Autonomic Dysfunction; QUIP: Questionnaire for Impulsive-Compulsive Disorders; LN: Letter-Number; MOCA: Montreal Cognitive Assessment. In response to these challenges, this study seeks to reconcile the disparities between conventional clinical practice and emerging computational techniques by developing and validating an interpretable machine learning framework for Parkinson’s disease diagnosis. This study aims to achieve two primary objectives: (1) to enhance the predictive accuracy of PD by optimally integrating diverse measures from the well-known PPMI repository, including both subjective self-reports and objective expert assessments; and (2) to offer clear, clinically relevant explanations for each model’s decision-making process, utilizing advanced SHAP tools. The research illustrates, utilizing actual clinical data, that the integration of both data types enhances diagnostic accuracy. It identifies the most important features, like tremor (from subjective tests) and bradykinesia and facial expression (from objective tests), and also shows how they affect predictions. This approach not only makes ML more useful for diagnosing PD, but it also builds trust and makes it easier to understand, setting a standard for future explainable AI frameworks in neurodegenerative disease research. The key contributions of this study are: a. Assembled subjective and objective features from PPMI to train and compare state-of-the-art classifiers under nested cross-validation. b. Embedded SHAP to quantify both local (patient-specific) and global (cohort-level) feature contributions in probability space, enabling intuitive statements like “this feature raised the PD probability by +0.05.” c. Separated global feature contributions for Healthy Control (HC) and PD cohorts and by data type, making it clear whether the subjective report or the objective assessment influences the differences. d. Identified well-known motor determinants (e.g., tremor, bradykinesia) and quantified their relative influence alongside daily and autonomic functions 2 Dataset and Methodology The data used in this study were obtained from the Parkinson’s Progression Markers Initiative (PPMI) 15 , a large-scale, longitudinal, and publicly available dataset designed to identify biomarkers of PD progression. The study methodology can be found at ppmi-info.org. The data were obtained from the Laboratory of NeuroImaging repository (LONI). The dataset includes a comprehensive collection of subjective (patient-reported) and objective (expert-assessed) neuropsychological and clinical assessments. The overall framework of our study is divided into four principal sections as shown in Figure 1 : data source description,

Read the complete text